Intervention of prehospital anticoagulation therapy on prophylaxis of venous thromboembolism following traumatic brain injury

doi:10.3877/cma.j.issn.2095-9141.2018.01.012

Abstract

Abstract:

Anticoagulation therapy including antiplatelet choice before hospital is increasing in common cardiovascular diseases. However, prehospital anticoagulation is presenting more complex and challenge for the neurosurgeon on prophylactic venous thromboembolism (VTE) of traumatic brain injury (TBI) patients. But the pharmacologic options of anticoagulation for VTE prophylaxis following TBI are related to the consequence of TBI treatment. Unfortunately we presently have not consistent viewpoint under this situation for selection of anticoagulants, over-dose reversal and monitoring of anticoagulation. Prehospital use of anticoagulants affect the VTE prophylaxis on two aspects: one is the side effects of anticoagulants, the other is that coagulation disorder may be produced following TBI. This review summarizes the advantages and drawbacks of various monitoring methods for frequent used coagulants before hospital in addition to their therapeutic characters, the goal is to supply a recommendation and guideline of VTE prophylaxis for TBI patients following prehospital anticoagulation therapy.

Key words: Traumatic brain injury, Anticoagulation therapy, Venous thromboembolism

Yueming Huang, Dongwu Yang, Gang Li, Guangkui Han, Changmeng Cui, Feng Jin. Intervention of prehospital anticoagulation therapy on prophylaxis of venous thromboembolism following traumatic brain injury[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2018, 04(01): 46-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2018.01.012

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2018/V04/I01/46

References 33

[1]	Nilsson OG,Lindgren A,Stahl N. et al. Incidence of intracerebral and subarachnoid hemorrhage in southern Sweden[J]. J Neurol Neurosurg Psychiatry, 2000, 69(5): 601-607
[2]	Nishijima DK,Shahlaie K,Sarkar K, et al. Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use[J]. Am J Emerg Med, 2013, 31(8): 1244-1247.
[3]	Hart RG,Pearce LA,Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007, 146(12): 857-867.
[4]	Apostolakis S,Sullivan RM,Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score [J]. Chest, 2013, 144(5): 1555-1563
[5]	周良辅.重视颅脑创伤后凝血功能障碍的诊断和治疗[J].中华创伤杂志, 2015, 31(8): 673-675.
[6]	Franko J,Kish KJ,O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma[J]. J Trauma, 2006, 61(1): 107-110.
[7]	Allard CB,Scarpelini S,Rhind SG, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage[J]. J Trauma, 2009, 67(5): 959-967.
[8]	Dzik WH. The James Blundell Award Lecture 2006: transfusion and the treatment of haemorrhage: past, present and future[J]. Transfus Med, 2007, 17(5): 367-374.
[9]	Karibe H,Hayashi T,Hirano T, et al. Surgical management of traumatic acute subdural hematoma in adults: a review[J]. Neurol Med Chir (Tokyo), 2014, 54(11): 887-894.
[10]	Lendrum RA,Kotze JP,Lockey DJ, et al. Case studies in prehospital care from London HEMS: pre-hospital administration of prothrombin complex concentrate to the head-injured patient[J]. Emerg Med J, 2013, 30(3): 247-248.
[11]	Raimondi P,Hylek EM,Aronis KN. Reversal agents for oral antiplatelet and anticoagulant treatment during bleeding events: current strategies[J]. Curr Pharm Des, 2017, 23(9): 1406-1423.
[12]	Siracuse JJ,Robich MP,Gautam S, et al. Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage[J]. Surgery, 2010, 148(4): 724-729; discussion 729-730.
[13]	Grandhi R,Harrison G,Voronovich Z, et al. Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients[J]. J Trauma Acute Care Surg, 2015, 78(3): 614-621.
[14]	Joseph B,Pandit V,Meyer D, et al. The significance of platelet count in traumatic brain injury patients on antiplatelet therapy[J]. J Trauma Acute Care Surg, 2014, 77(3): 417-421.
[15]	Washington CW,Schuerer DJ,Grubb RL Jr. Platelet transfusion: an unnecessary risk for mild traumatic brain injury patients on antiplatelet therapy[J]. J Trauma, 2011, 71(2): 358-363.
[16]	Joseph B,Aziz H,Pandit V, et al. Low-dose aspirin therapy is not a reason for repeating head computed tomographic scans in traumatic brain injury: a prospective study[J]. J Surg Res, 2014, 186(1): 287-291.
[17]	Davenport R. Pathogenesis of acute traumatic coagulopathy[J]. Transfusion, 2013, 53 Suppl 1: 23S-27S.
[18]	Fortuna GR,Mueller EW,James LE, et al. The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury[J]. Surgery, 2008, 144(4): 598-603; discussion 603-605.
[19]	Olesen JB,Sorensen R,Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na?ve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013[J]. Europace, 2015, 17(2): 187-193.
[20]	Hylek EM,Held C,Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes[J]. J Am Coll Cardiol, 2014, 63(20): 2141-2147.
[21]	Flaker GC,Eikelboom JW,Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial[J]. Stroke, 2012, 43(12): 3291-3297.
[22]	Abraham NS,Singh S,Alexander GC, et al. Comparative risK of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study[J]. BMJ, 2015, 350: h1857.
[23]	Pozzessere A,Grotts J,Kaminski S. Dabigatran use does not increase intracranial hemorrhage in traumatic geriatric falls when compared with warfarin[J]. Am Surg, 2015, 81(10): 1039-1042.
[24]	Goldhaber SZ,Polak JF,Feldstein ML, et al. Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis[J]. Am J Cardiol, 1994, 73(1): 75-79.
[25]	Medcalf RL. The traumatic side of fibrinolysis[J]. Blood, 2015, 125(16): 2457-2458.
[26]	Bolliger D,Zenklusen U,Tanaka KA. Point-of-care coagulation management algorithms during ECMO support: are we there yet?[J]. Minerva Anestesiol, 2016, 82(9): 1000-1009.
[27]	Scudday T,Brasel K,Webb T, et al. Safety and efficacy of prophylaCTic anticoagulation in patients with traumatic brain injury[J]. J Am Coll Surg, 2011, 213(1): 148-153; discussion 153-154.
[28]	Li S,Marks JA,Eisenstadt R, et al. Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo[J]. J Trauma Acute Care Surg, 2015, 79(1): 78-84.
[29]	Goldstein JN,Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage?[J]. Cleve Clin J Med, 2010, 77(11): 791-799.
[30]	Hawryluk GW,Austin JW,Furlan JC, et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk[J]. J Thromb Haemost, 2010, 8(7): 1500-1508.
[31]	Yeon JY,Kong DS,Hong SC. Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage[J]. J Neurotrauma, 2012, 29(7): 1334-1341.
[32]	Ruff CT,Giugliano RP,Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921): 955-962.
[33]	Shrestha S,Coy S,Bekelis K. Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke[J]. Curr Pharm Des, 2017, 23(9): 1377-1391.

Please choose a citation manager

Content to export